ArticleRespiratory research2026
Distinct pulmonary pathophysiological mechanisms in COPD, bronchiectasis, and primary immunodeficiency: a multi-omics investigation of disease heterogeneity via sputum and blood profiling.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchiectasis (BE), Chronic Obstructive Pulmonary Disease (COPD) and Primary Immunodeficiency (PID) are distinct respiratory conditions that share features such as chronic inflammation, airway obstruction, and recurrent infections. Despite distinct underlying causes, disease manifestations often overlap clinically, complicating diagnosis and treatment. We aimed to characterise shared and disease-specific immune mechanisms in BE, COPD, and PID using a multi-omics approach across blood and sputum.
methodsAdults with BE, COPD, PID, and healthy controls underwent serum and sputum protein quantification, sputum proteomics, and transcriptomic profiling of sputum and blood. Neutrophil fractions were included as covariates in transcriptomic analyses.
resultsDistinct clinical profiles were observed across disease groups. Serum analyses showed changes in inflammatory and extracellular matrix markers, particularly in BE and COPD. Sputum from BE patients showed elevated inflammatory markers and pathogen burden. Proteomic profiling demonstrated that BE and COPD shared neutrophil-driven inflammatory pathways, while PID exhibited a unique humoral immune signature. Transcriptomic analyses further confirmed neutrophil abundance as a major driver of gene expression variation across disease cohorts. After adjusting for neutrophil fractions, disease-specific differentially expressed genes (DEG) were identified, including OLFML2B, FZD2, and STAB1 in BE, and GPR15, METTL7B, and RNASE1 in COPD. PID samples showed no significant DEGs but enrichment of interferon signalling pathways. CD177 and DEFA3 were overexpressed beyond variation driven by neutrophil abundance, highlighting association with key inflammatory drivers in BE and COPD.
conclusionsThis study uses an integrative multi-omics analysis to improve the understanding of disease heterogeneity and distinct inflammatory pathways in BE, COPD and PID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.